Stryker (SYK) Stock Forecast & Price Target

$383.32 -5.47 (-1.41%)

Closing price 09/12/2025 03:59 PM Eastern

Extended Trading

$383.37 +0.05 (+0.01%)

As of 09/12/2025 07:41 PM Eastern

Compare

Stryker - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Moderate Buy

Based on 18 Analyst Ratings

Sell
0

Hold
4

Buy
14

Based on 18 Wall Street analysts who have issued ratings for Stryker in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 4 have given a hold rating, and 14 have given a buy rating for SYK.

Consensus Price Target

$431.42
12.55% Upside

According to the 18 analysts' twelve-month price targets for Stryker, the average price target is $431.42. The highest price target for SYK is $456.00, while the lowest price target for SYK is $370.00. The average price target represents a forecasted upside of 12.55% from the current price of $383.32.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for SYK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Stryker and its competitors.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SYK Analyst Ratings Over Time

Type	Current Forecast 9/13/24 to 9/13/25	1 Month Ago 8/14/24 to 8/14/25	3 Months Ago 6/15/24 to 6/15/25	1 Year Ago 9/14/23 to 9/13/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	15 Buy rating(s)	15 Buy rating(s)	15 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$431.42	$430.10	$427.30	$378.58
Forecasted Upside	12.55% Upside	13.62% Upside	13.34% Upside	2.27% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

SYK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SYK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Stryker Stock vs. The Competition

Type	Stryker	Medical Companies	S&P 500
Consensus Rating Score	2.78	2.78	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	12.55% Upside	17,477.86% Upside	10.72% Upside
News Sentiment Rating	Very Positive News See Recent SYK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/4/2025	Truist Financial 3 of 5 stars	Richard Newitter Not Rated	Set Target	Hold	$410.00 ➝ $415.00	+8.79%
8/1/2025	Wells Fargo & Company 3 of 5 stars	Larry Biegelsen 1 of 5 stars	Boost Target	Overweight	$435.00 ➝ $445.00	+17.27%
8/1/2025	Needham & Company LLC 2 of 5 stars	Mike Matson 1 of 5 stars	Boost Target	Buy	$442.00 ➝ $448.00	+13.89%
7/14/2025	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
7/8/2025	Evercore ISI Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vijay Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$390.00 ➝ $415.00	+5.80%
5/22/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$443.00 ➝ $455.00	+20.09%
5/5/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lee Hambright Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$450.00	+17.24%
5/5/2025	JMP Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Turkaly Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Perform
5/2/2025	Roth Mkm Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason Wittes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$405.00 ➝ $456.00	+20.75%
3/4/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$422.00	+12.41%
Get the Latest News and Ratings for SYK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Stryker and its competitors with MarketBeat's FREE daily newsletter.
2/10/2025	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$418.00 ➝ $443.00	+13.18%
2/3/2025	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Toung Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$450.00	+17.62%
1/29/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$425.00 ➝ $435.00	+11.57%
1/29/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$420.00 ➝ $445.00	+12.68%
1/29/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$400.00 ➝ $440.00	+11.41%
1/29/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kyle Rose Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$420.00 ➝ $435.00	+10.15%
12/2/2024	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$370.00 ➝ $445.00	+13.48%
10/30/2024	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight	$380.00 ➝ $420.00	+17.04%
10/30/2024	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Neutral	$366.00 ➝ $370.00	+2.61%
10/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$378.00 ➝ $405.00	+12.73%
9/10/2024	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$405.00	+11.64%
4/11/2024	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$365.00 ➝ $400.00	+15.82%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 05:44 PM ET.

Should I Buy Stryker Stock? SYK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 12, 2025. Please send any questions or comments about these Stryker pros and cons to contact@marketbeat.com.

Stryker
Bull Case

Here are some ways that investors could benefit from investing in Stryker Co.:

The company recently reported earnings per share (EPS) of $3.13, exceeding analyst expectations, which indicates strong financial performance and potential for growth.
Stryker Co. has shown a year-over-year revenue increase of 11.1%, suggesting robust demand for its medical technology products.
The current stock price is around $455, reflecting positive market sentiment and potential for further appreciation.
With a dividend yield of 0.9% and a payout ratio of 44.50%, Stryker Co. offers a reliable income stream for investors while maintaining a healthy balance between reinvesting in the business and returning value to shareholders.
The company has a solid return on equity of 23.94%, indicating effective management and profitability relative to shareholder equity.

Stryker
Bear Case

Investors should be bearish about investing in Stryker Co. for these reasons:

The debt-to-equity ratio of 0.70 suggests that the company is somewhat reliant on debt financing, which could pose risks in a rising interest rate environment.
Despite recent growth, the medical technology sector can be highly competitive and subject to regulatory changes, which may impact future profitability.
Analysts have mixed ratings, with some maintaining a "hold" rating, indicating uncertainty about the stock's short-term performance.
The company's quarterly dividend payment, while consistent, may not be sufficient to attract all income-focused investors, especially in a low-yield environment.
Market volatility can affect stock prices, and Stryker Co. is not immune to broader market trends that could lead to price fluctuations.

SYK Forecast - Frequently Asked Questions

: According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Stryker is $431.42, with a high forecast of $456.00 and a low forecast of $370.00.
: 18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last twelve months. There are currently 4 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SYK shares.
: According to analysts, Stryker's stock has a predicted upside of 12.55% based on their 12-month stock forecasts.
: Stryker has been rated by research analysts at BTIG Research, Evercore ISI, Needham & Company LLC, Truist Financial, and Wells Fargo & Company in the past 90 days.
: Analysts like Stryker less than other "medical" companies. The consensus rating score for Stryker is 2.78 while the average consensus rating score for "medical" companies is 2.78. Learn more on how SYK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:SYK) was last updated on 9/13/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stryker (SYK) Stock Forecast & Price Target